Scholarlink

<p>Advances in cancer treatment have increased survival rates; however, chemotherapy drugs can impair ovarian reserve via pathways such as PI3K/AKT and Hippo, leading to infertility. Conventional fertility preservation options have limitations. Therefore, agents that prevent or reduce the ovarian side effects of chemotherapy should be investigated. This review explored treatments for preserving ovarian reserve by regulating the PI3K/AKT and Hippo pathways during chemotherapy. When treated with cyclophosphamide and cisplatin, 33 agents in the articles were implicated in the PI3K/AKT and/or Hippo pathways, most of which target the PI3K/AKT pathway. It can be concluded that controlling both the PI3K/AKT and Hippo pathways, but specifically the PI3K/AKT pathway, can help maintain ovarian reserve against these two chemotherapy drugs and provide hope for increased fertility in patients receiving chemotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Preventing chemotherapy-induced ovarian damage through PI3K/AKT and Hippo pathway regulation

  • 期刊论文

  • 发表日期：

    2025年3月28日

查看全文
  • Negin Zatalian,
  • Azam Dalman,
  • Hamid Gourabi

摘要

Advances in cancer treatment have increased survival rates; however, chemotherapy drugs can impair ovarian reserve via pathways such as PI3K/AKT and Hippo, leading to infertility. Conventional fertility preservation options have limitations. Therefore, agents that prevent or reduce the ovarian side effects of chemotherapy should be investigated. This review explored treatments for preserving ovarian reserve by regulating the PI3K/AKT and Hippo pathways during chemotherapy. When treated with cyclophosphamide and cisplatin, 33 agents in the articles were implicated in the PI3K/AKT and/or Hippo pathways, most of which target the PI3K/AKT pathway. It can be concluded that controlling both the PI3K/AKT and Hippo pathways, but specifically the PI3K/AKT pathway, can help maintain ovarian reserve against these two chemotherapy drugs and provide hope for increased fertility in patients receiving chemotherapy.